Cellectar LLC is a radiopharmaceuticals company that designs and develops products to detect, treat and monitor a wide variety of human cancers. Cellectar\'s novel product candidates combine lipid-like molecules, phospholipid ethers (PLEs), with radioisotopes that destroy malignant cells. Cellectar\'s products\' unique mechanism of action is based on their selective accumulation and retention in malignant tumors and not normal cells. The company\'s operations are based in Madison, WI. Cellectar haspreviously raised approximately $9.0 million from angel investors; including Continuum Investment Partners